πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

RIGEL PHARMACEUTICALS Patents

Full USPTO pharma patent portfolio for RIGEL PHARMACEUTICALS β€” grant dates, expiration, and drug cross-links.

Patents
373
Expiring ≀24m
18

Quick answer

RIGEL PHARMACEUTICALS has 373 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 18 expire within 24 months β€” use filters for patent-cliff planning.

Page 1 of 8

  1. US 12384775

    Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12357623

    Method for treating a disease or condition using a pyrazole compound or formulation thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12331036

    Heterocyclic RIP1 kinase inhibitors

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12297202

    RIP1K inhibitors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12263180

    Method for treatment of COVID-19-associated conditions

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12227508

    TGF-Ξ² inhibitors

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12156880

    Heterocyclic RIP1 kinase inhibitors

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12116354

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12043629

    RIP1K inhibitors

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12043620

    Benzazole compounds and methods for making and using the compounds

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11993594

    IRAK inhibitors and method for making and using

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11963958

    RET inhibitor for use in treating cancer having a RET alteration

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11939317

    Amide compounds and method for making and using

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11827628

    Compositions and methods for inhibition of the JAK pathway

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11672791

    Tyrosine kinase inhibitors

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11667643

    RIP1K inhibitors

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11667611

    Compositions and methods for inhibition of the JAK pathway

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11584758

    RIP1K inhibitors

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11578078

    Heterocyclic RIP1 inhibitory compounds

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11564930

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11530194

    Amide compounds and method for making and using

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11524955

    2,4-diamino-pyrimidine compounds and method for making and using the compounds

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11492349

    IRAK inhibitors and method for making and using

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11479543

    Heterocyclic RIP1 kinase inhibitors

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11472782

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11466018

    TGF-Ξ² inhibitors

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11407736

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11377428

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11370764

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11370765

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11370787

    Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11370808

    Pyrazole compounds and methods for making and using the compounds

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11352360

    TGF-beta inhibitors

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11332451

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11299486

    Benzazole compounds and methods for making and using the compounds

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11279686

    Nrf2 activating compounds and uses thereof

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11230554

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11220496

    Compounds and method for treating autoimmune diseases

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11198689

    Compositions and methods for inhibition of the JAK pathway

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11174246

    Direct AMPK activators

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11174251

    Compositions and methods for inhibition of the JAK pathway

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11129819

    Fumarate analogs and uses thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11110082

    Tyrosine kinase inhibitors

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11104737

    ACVR2A-specific antibody and method of treatment of muscle atrophy

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11059814

    Kinase inhibitors and methods for making and using

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11021468

    TGF-ß inhibitors

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11007193

    2,4-pyrimidinediamine compounds and their uses

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10975064

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does RIGEL PHARMACEUTICALS have?

373 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do RIGEL PHARMACEUTICALS patents expire?

18 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.